The historical rank and industry rank for Gilead Sciences's Price-to-Tangible-Book or its related term are showing as below:
During the past 13 years, Gilead Sciences's highest Price to Tangible Book Ratio was 52.34. The lowest was 10.73. And the median was 20.22.
GILD's Price-to-Tangible-Book is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.36 * Ranked among companies with meaningful Price-to-Tangible-Book only.
Gilead Sciences Price-to-Tangible-Book Historical Data
The historical data trend for Gilead Sciences's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Gilead Sciences's Price-to-Tangible-Book
For the Drug Manufacturers - General subindustry, Gilead Sciences's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gilead Sciences's Price-to-Tangible-Book Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Gilead Sciences's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Gilead Sciences Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Gilead Sciences's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Gilead Sciences (Gilead Sciences) Business Description
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GILD has been successfully added to your 